| scholarly article | Q13442814 |
| P50 | author | Almudena Crooke | Q92351581 |
| P2093 | author name string | Fernando Huete-Toral | |
| Jesus Pintor | |||
| Basilio Colligris | |||
| P2860 | cites work | A pilot study of IL-1 inhibition by anakinra in acute gout | Q21195421 |
| Tocilizumab | Q24655317 | ||
| Cellular targeting in autoimmunity | Q26824580 | ||
| Design of a superior cytokine antagonist for topical ophthalmic use | Q27676526 | ||
| Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery | Q28244137 | ||
| Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? | Q28258068 | ||
| Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study | Q34066784 | ||
| Diagnosis of dry eye. | Q34391935 | ||
| Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. | Q34544207 | ||
| Effectiveness of artificial tears in the management of evaporative dry eye. | Q34632803 | ||
| Dry eye as a mucosal autoimmune disease | Q34647761 | ||
| A clinical study of the efficacy of topical corticosteroids on dry eye. | Q34943771 | ||
| The relationship between clinical signs and dry eye symptoms. | Q35208749 | ||
| Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye | Q35589451 | ||
| Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb | Q35854966 | ||
| Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease | Q35907009 | ||
| Efficacy of topical blockade of interleukin-1 in experimental dry eye disease | Q36044544 | ||
| Survey of eye practitioners' attitudes towards diagnostic tests and therapies for dry eye disease | Q36201636 | ||
| A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients | Q36296284 | ||
| Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study | Q36313759 | ||
| Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test | Q37213371 | ||
| Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis | Q37478085 | ||
| A review of hyaluronan and its ophthalmic applications | Q37819218 | ||
| Current evidence for topical azithromycin 1% ophthalmic solution in the treatment of blepharitis and blepharitis-associated ocular dryness | Q37928322 | ||
| Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. | Q38019465 | ||
| Evaluation of dry eye. | Q38021053 | ||
| Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting | Q38151227 | ||
| Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. | Q38180652 | ||
| Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles. | Q39504402 | ||
| Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain | Q40026647 | ||
| Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118) | Q40356553 | ||
| Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. | Q41316622 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome | Q41936291 | ||
| Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome | Q41938505 | ||
| Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye | Q42060377 | ||
| Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye. | Q42628203 | ||
| Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite) solution in the treatment of ocular infections | Q42789151 | ||
| The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments | Q43637103 | ||
| Ecabet sodium attenuates reactive oxygen species produced by neutrophils after priming with bacterial lipopolysaccharides | Q43773497 | ||
| A preliminary investigation into the effects of ocular lubricants on higher order aberrations in normal and dry eye subjects | Q43976677 | ||
| INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model | Q44131963 | ||
| Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva | Q44797192 | ||
| The repeatability of clinical measurements of dry eye. | Q44845090 | ||
| Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model | Q44981253 | ||
| A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance | Q45056544 | ||
| The lack of association between signs and symptoms in patients with dry eye disease | Q45122466 | ||
| Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface | Q45158772 | ||
| Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification | Q45689094 | ||
| The relationship between dry eye symptoms and lipid layer thickness | Q46077930 | ||
| Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits | Q46259324 | ||
| Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension | Q46526215 | ||
| Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials | Q46917136 | ||
| Clinical tests for successful contact lens wear: relationship and predictive potential | Q47314627 | ||
| An objective approach to dry eye disease severity | Q48343172 | ||
| Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. | Q50490131 | ||
| Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. | Q50522217 | ||
| A multicenter, double-blind, parallel group, placebo-controlled clinical study to examine the safety and efficacy of T-Clair SPHP700-3 in the management of mild to moderate dry eye in adults. | Q50533859 | ||
| Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena). | Q50558766 | ||
| The diagnosis and characteristics of moderate dry eye in non-contact lens wearers. | Q51466389 | ||
| An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. | Q54576777 | ||
| Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. | Q54643325 | ||
| Effect of the counterion behavior on the frictional–compressive properties of chondroitin sulfate solutions | Q55952850 | ||
| An overview on dry eye treatment: approaches for cyclosporin a delivery | Q57378877 | ||
| Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry | Q57612819 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 1371-1390 | |
| P577 | publication date | 2014-04-29 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | An update on dry eye disease molecular treatment: advances in drug pipelines | |
| P478 | volume | 15 |
| Q64226436 | A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease |
| Q26747220 | Advanced drug delivery and targeting technologies for the ocular diseases |
| Q64102864 | Advances in the treatment of rhegmatogenous retinal detachment |
| Q38541101 | Current and Emerging Therapeutic Strategies for the Treatment of Meibomian Gland Dysfunction (MGD). |
| Q39404635 | Dry Eye Management: Targeting the Ocular Surface Microenvironment. |
| Q58795856 | Dry eye symptoms and impact on vision-related function across International Task Force guidelines severity levels in the United States |
| Q26778628 | Human Serum Eye Drops in Eye Alterations: An Insight and a Critical Analysis |
| Q26740643 | Immunomodulation on the ocular surface: a review |
| Q38984001 | Investigational drugs in dry eye disease |
| Q36326806 | Preclinical mouse model to monitor live Muc5b-producing conjunctival goblet cell density under pharmacological treatments |
| Q50110517 | Therapeutic inhibitors for the treatment of dry eye syndrome. |
Search more.